Hepatocyte-Specific Loss of PPARγ Protects Mice From NASH and Increases the Therapeutic Effects of Rosiglitazone in the Liver

BACKGROUND & AIMS: Nonalcoholic steatohepatitis (NASH) is commonly observed in patients with type 2 diabetes, and thiazolidinediones (TZD) are considered a potential therapy for NASH. Although TZD increase insulin sensitivity and partially reduce steatosis and alanine aminotransferase, the effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Samuel M., Pusec, Carolina M., Norris, Gregory H., De Jesus, Adam, Diaz-Ruiz, Alberto, Muratalla, Jose, Sarmento-Cabral, Andre, Guzman, Grace, Layden, Brian T., Cordoba-Chacon, Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005819/
https://www.ncbi.nlm.nih.gov/pubmed/33444819
http://dx.doi.org/10.1016/j.jcmgh.2021.01.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005819/
https://www.ncbi.nlm.nih.gov/pubmed/33444819
http://dx.doi.org/10.1016/j.jcmgh.2021.01.003

Ejemplares similares